Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway

被引:36
作者
Hodroj, Mohammad Hassan [1 ]
Jardaly, Achraf [1 ]
Raad, Sarah Abi [1 ]
Zouein, Annalise [1 ]
Rizk, Sandra [1 ]
机构
[1] Lebanese Amer Univ, Dept Nat Sci, Beirut 11022801, Lebanon
关键词
topotecan; andrographolide; Andrographis paniculata; acute myeloid leukemia; apoptosis; TOPOISOMERASE-I INHIBITOR; CHILDRENS ONCOLOGY GROUP; PHASE-II; PROSTATE-CANCER; LYMPHOMA-CELLS; CYCLE ARREST; COMBINATION; RADIOTHERAPY; NEUROBLASTOMA; GEMCITABINE;
D O I
10.2147/CMAR.S160924
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Topotecan (TP) is an anticancer drug acting as topoisomerase I inhibitor that is used in the treatment of many types of cancers including leukemia, but it has significant side effects. Andrographolide, a compound extracted from Andrographis paniculata, was recently proven to inhibit the growth of cancer cells and can induce apoptosis. The aim of this study is to investigate the possible synergism between TP and andrographolide in acute myeloid cells in vitro. Materials and methods: U937 acute myeloid leukemic cells were cultured using Roswell Park Memorial Institute (RPMI) medium and then treated for 24 h with TP and andrographolide prepared through the dilution of dimethyl sulfoxide (DMSO) stocks with RPMI on the day of treatment. Cell proliferation was assessed using cell proliferation assay upon treatment with both compounds separately and in combination. Cell-cycle study and apoptosis detection were performed by staining the cells with propidium iodide (PI) stain and Annexin V/PI stain, respectively, followed by flow cytometry analysis. Western blotting was used to assess the expression of various proteins involved in apoptotic pathways. Results: Both TP and andrographolide showed an antiproliferative effect in a dose-dependent manner when applied on U937 cells separately; however, pretreating the cells with andrographolide before applying TP exhibited a synergistic effect with lower inhibitory concentrations (half-maximal inhibitory concentration). Treating the cells with TP alone led to specific cell-cycle arrest at S phase that was more prominent upon pretreatment combination with andrographolide. Using Annexin V/PI staining to assess the proapoptotic effect following the pretreatment combination showed an increase in the number of apoptotic cells, which was supported by the Western blot results that manifested an upregulation of several proapoptotic proteins expression. Conclusion: The pretreatment of U937 with andrographolide followed by low doses of TP showed an enhancement in inducing apoptosis when compared to the application of each compound separately.
引用
收藏
页码:1079 / 1088
页数:10
相关论文
共 41 条
[1]   Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells [J].
Adams, David J. ;
Sandvold, Marit L. ;
Myhren, Finn ;
Jacobsen, Tove F. ;
Giles, Frank ;
Rizzieri, David A. .
LEUKEMIA & LYMPHOMA, 2008, 49 (04) :786-797
[2]   Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer [J].
Aljuffali, Ibrahim A. ;
Mock, Jason N. ;
Costyn, Leah J. ;
Ha Nguyen ;
Nagy, Tamas ;
Cummings, Brian S. ;
Arnold, Robert D. .
CANCER BIOLOGY & THERAPY, 2011, 12 (05) :407-420
[3]   Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas [J].
Carcaboso, Angel M. ;
Elmeliegy, Mohamed A. ;
Shen, Jun ;
Juel, Stephen J. ;
Zhang, Ziwei M. ;
Calabrese, Christopher ;
Tracey, Lorraine ;
Waters, Christopher M. ;
Stewart, Clinton F. .
CANCER RESEARCH, 2010, 70 (11) :4499-4508
[4]  
Chang Jing, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P1238, DOI 10.3736/jcim20081206
[5]   Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan [J].
Chaturvedi, Nagendra K. ;
McGuire, Timothy R. ;
Coulter, Don W. ;
Shukla, Ashima ;
McIntyre, Erin M. ;
Sharp, John Graham ;
Joshi, Shantaram S. .
ONCOTARGET, 2016, 7 (12) :15215-15229
[6]   Optimization of liposomal topotecan for use in treating neuroblastoma [J].
Chernov, Lina ;
Deyell, Rebecca J. ;
Anantha, Malathi ;
Dos Santos, Nancy ;
Gilabert-Oriol, Roger ;
Bally, Marcel B. .
CANCER MEDICINE, 2017, 6 (06) :1240-1254
[7]   A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group [J].
Chintagumpala, Murali M. ;
Friedman, Henry S. ;
Stewart, Clinton F. ;
Kepner, James ;
McLendon, Roger E. ;
Modrich, Paul L. ;
McCluggage, Charles ;
Burger, Peter ;
Holmes, Emi ;
Thompson, Stephen ;
Rutka, James ;
Michalski, Jeff ;
Woo, Shiao ;
Blaney, Susan M. ;
Kun, Larry E. ;
Horowitz, Marc E. .
JOURNAL OF NEURO-ONCOLOGY, 2006, 77 (02) :193-198
[8]   Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix [J].
Frumovitz, M. ;
Munsell, M. F. ;
Burzawa, J. K. ;
Byers, L. A. ;
Ramalingam, P. ;
Brown, J. ;
Coleman, R. L. .
GYNECOLOGIC ONCOLOGY, 2017, 144 (01) :46-50
[9]   Feasibility and efficacy of salvage radiotherapy with concurrent weekly topotecan in recurrent primitive neuroectodermal tumor [J].
Ghosh, I ;
Mallick, I ;
Ray, S. .
INDIAN JOURNAL OF CANCER, 2015, 52 (01) :25-26
[10]   Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile [J].
Giovannetti, E ;
Mey, V ;
Danesi, R ;
Basolo, F ;
Barachini, S ;
Deri, M ;
Del Tacca, M .
BRITISH JOURNAL OF CANCER, 2005, 92 (04) :681-689